Pioglitazone

Generic Name
Pioglitazone
Brand Names
Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3S
CAS Number
111025-46-8
Unique Ingredient Identifier
X4OV71U42S
Background

Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions
Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
Associated Therapies
-

Pioglitazone Incretin Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-04-11
Last Posted Date
2011-02-02
Lead Sponsor
University of Vermont
Target Recruit Count
24
Registration Number
NCT00656864
Locations
🇺🇸

University of Vermont, South Burlington, Vermont, United States

Exercise and Pioglitazone for HIV-Metabolic Syndromes

First Posted Date
2008-03-20
Last Posted Date
2013-10-23
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
44
Registration Number
NCT00639457
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-03-12
Last Posted Date
2017-07-19
Lead Sponsor
Fernando Holguin
Target Recruit Count
23
Registration Number
NCT00634036
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Vermont, Colchester, Vermont, United States

Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

First Posted Date
2008-03-12
Last Posted Date
2012-06-05
Lead Sponsor
Xin Gao
Target Recruit Count
184
Registration Number
NCT00633282
Locations
🇨🇳

Department of Endocrinology and Metabolism,Shanghai Clinical Center of Diabetes,Shanghai Institute of Diabetes,The sixth people's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China

🇨🇳

Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University,, Shanghai, Shanghai, China

🇨🇳

Department of Endocrinology and Metabolism,The Fifth People's Hospital,Fudan University, Shanghai, Shanghai, China

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

First Posted Date
2008-02-07
Last Posted Date
2008-02-07
Lead Sponsor
Skane University Hospital
Target Recruit Count
36
Registration Number
NCT00609856
Locations
🇸🇪

Malmö University Hospital, Malmö, Sweden

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

Phase 3
Completed
Conditions
First Posted Date
2008-01-23
Last Posted Date
2017-01-09
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
242
Registration Number
NCT00598793
Locations
🇺🇸

Novo Nordisk Investigational Site, Renton, Washington, United States

Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

First Posted Date
2008-01-18
Last Posted Date
2008-01-18
Lead Sponsor
Yonsei University
Target Recruit Count
83
Registration Number
NCT00598013
Locations
🇰🇷

Yonsei University College of Medicine, Seoul, Korea, Republic of

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

First Posted Date
2008-01-04
Last Posted Date
2013-03-15
Lead Sponsor
Mayo Clinic
Target Recruit Count
36
Registration Number
NCT00586261
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Mechanisms Underlying Metabolic Syndrome in Obesity

First Posted Date
2007-12-24
Last Posted Date
2017-06-15
Lead Sponsor
Philip Kern
Target Recruit Count
70
Registration Number
NCT00579813
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

University of Kentucky, Lexington, Kentucky, United States

© Copyright 2024. All Rights Reserved by MedPath